FGFR3 Fusion is an inclusion criterion in 21 clinical trials for malignant solid tumor, of which 15 are open and 6 are closed. Of the trials that contain FGFR3 Fusion and malignant solid tumor as inclusion criteria, 6 are phase 1 (1 open), 5 are phase 1/phase 2 (4 open), and 10 are phase 2 (10 open) [5].

FGFR3 Fusion is an inclusion criterion in 13 clinical trials for urothelial carcinoma, of which 12 are open and 1 is closed. Of the trials that contain FGFR3 Fusion and urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open), 6 are phase 1/phase 2 (5 open), 3 are phase 2 (3 open), 2 are phase 3 (2 open), and 1 is no phase specified (1 open) [5].

FGFR3 Fusion is an inclusion criterion in 8 clinical trials for acute lymphoblastic leukemia, of which 7 are open and 1 is closed. Of the trials that contain FGFR3 Fusion and acute lymphoblastic leukemia as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), 3 are phase 2 (3 open), and 1 is phase 2/phase 3 (1 open) [5].

FGFR3 Fusion is an inclusion criterion in 6 clinical trials for cholangiocarcinoma, of which 6 are open and 0 are closed. Of the trials that contain FGFR3 Fusion and cholangiocarcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [5].

FGFR3 Fusion is an inclusion criterion in 5 clinical trials for cancer, of which 1 is open and 4 are closed. Of the trials that contain FGFR3 Fusion and cancer as inclusion criteria, 1 is phase 1 (0 open) and 4 are phase 2 (1 open) [5].

FGFR3 Fusion is an inclusion criterion in 5 clinical trials for non-small cell lung carcinoma, of which 4 are open and 1 is closed. Of the trials that contain FGFR3 Fusion and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 4 are phase 2 (3 open) [5].

FGFR3 Fusion is an inclusion criterion in 5 clinical trials for B-cell acute lymphoblastic leukemia, of which 3 are open and 2 are closed. Of the trials that contain FGFR3 Fusion and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open), 3 are phase 2 (1 open), and 1 is phase 2/phase 3 (1 open) [5].

FGFR3 Fusion is an inclusion criterion in 4 clinical trials for bladder carcinoma, of which 3 are open and 1 is closed. Of the trials that contain FGFR3 Fusion and bladder carcinoma as inclusion criteria, 3 are phase 1 (2 open) and 1 is no phase specified (1 open) [5].

FGFR3 Fusion is an inclusion criterion in 3 clinical trials for squamous cell lung carcinoma, of which 3 are open and 0 are closed. Of the trials that contain FGFR3 Fusion and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is no phase specified (1 open) [5].

FGFR3 Fusion is an inclusion criterion in 3 clinical trials for endometrial carcinoma, of which 3 are open and 0 are closed. Of the trials that contain FGFR3 Fusion and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

FGFR3 Fusion is an inclusion criterion in 3 clinical trials for gastric carcinoma, of which 3 are open and 0 are closed. Of the trials that contain FGFR3 Fusion and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

FGFR3 Fusion is an inclusion criterion in 3 clinical trials for acute myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain FGFR3 Fusion and acute myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [5].

FGFR3 Fusion is an inclusion criterion in 3 clinical trials for multiple myeloma, of which 3 are open and 0 are closed. Of the trials that contain FGFR3 Fusion and multiple myeloma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [5].

FGFR3 Fusion is an inclusion criterion in 2 clinical trials for breast carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FGFR3 Fusion and breast carcinoma as inclusion criteria, 2 are phase 1 (1 open) [5].

FGFR3 Fusion is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FGFR3 Fusion and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 2 (1 open) [5].

FGFR3 Fusion is an inclusion criterion in 2 clinical trials for sarcoma, of which 2 are open and 0 are closed. Of the trials that contain FGFR3 Fusion and sarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

FGFR3 Fusion is an inclusion criterion in 2 clinical trials for mixed phenotype acute leukemia, of which 2 are open and 0 are closed. Of the trials that contain FGFR3 Fusion and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2/phase 3 (1 open) [5].

FGFR3 Fusion is an inclusion criterion in 2 clinical trials for myelodysplastic syndromes, of which 2 are open and 0 are closed. Of the trials that contain FGFR3 Fusion and myelodysplastic syndromes as inclusion criteria, 2 are phase 2 (2 open) [5].

FGFR3 Fusion is an inclusion criterion in 2 clinical trials for non-muscle invasive bladder carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FGFR3 Fusion and non-muscle invasive bladder carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].

FGFR3 Fusion is an inclusion criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 Fusion and bladder urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

FGFR3 Fusion is an inclusion criterion in 1 clinical trial for glioblastoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 Fusion and glioblastoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

FGFR3 Fusion is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 Fusion and anaplastic astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

FGFR3 Fusion is an inclusion criterion in 1 clinical trial for intrahepatic cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 Fusion and intrahepatic cholangiocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

FGFR3 Fusion is an inclusion criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 Fusion and colorectal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR3 Fusion is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 Fusion and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR3 Fusion is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 Fusion and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

FGFR3 Fusion is an inclusion criterion in 1 clinical trial for B-cell lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 Fusion and B-cell lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [5].

FGFR3 Fusion is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 Fusion and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR3 Fusion is an inclusion criterion in 1 clinical trial for chronic myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 Fusion and chronic myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [5].

FGFR3 Fusion is an inclusion criterion in 1 clinical trial for chronic myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 Fusion and chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR3 Fusion is an inclusion criterion in 1 clinical trial for extrahepatic cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 Fusion and extrahepatic cholangiocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

FGFR3 Fusion is an inclusion criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 Fusion and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR3 Fusion is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 Fusion and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR3 Fusion is an inclusion criterion in 1 clinical trial for lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 Fusion and lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [5].

FGFR3 Fusion is an inclusion criterion in 1 clinical trial for lymphocytic neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 Fusion and lymphocytic neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR3 Fusion is an inclusion criterion in 1 clinical trial for mixed phenotype acute leukemia, B/myeloid, NOS, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 Fusion and mixed phenotype acute leukemia, B/myeloid, NOS as inclusion criteria, 1 is phase 2/phase 3 (1 open) [5].

FGFR3 Fusion is an inclusion criterion in 1 clinical trial for mixed phenotype acute leukemia, T/myeloid, NOS, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 Fusion and mixed phenotype acute leukemia, T/myeloid, NOS as inclusion criteria, 1 is phase 2/phase 3 (1 open) [5].

FGFR3 Fusion is an inclusion criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 Fusion and myeloid neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR3 Fusion is an inclusion criterion in 1 clinical trial for myeloproliferative neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 Fusion and myeloproliferative neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

FGFR3 Fusion is an inclusion criterion in 1 clinical trial for non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 Fusion and non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR3 Fusion is an inclusion criterion in 1 clinical trial for secondary acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 Fusion and secondary acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR3 Fusion is an inclusion criterion in 1 clinical trial for small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FGFR3 Fusion and small cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

FGFR3 Fusion is an inclusion criterion in 1 clinical trial for T-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 Fusion and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 2/phase 3 (1 open) [5].

FGFR3 Fusion is an inclusion criterion in 1 clinical trial for T-cell lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 Fusion and T-cell lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [5].

FGFR3 Fusion is an inclusion criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 Fusion and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [5].